These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 32463026)

  • 41. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area.
    Long SW; Olsen RJ; Christensen PA; Bernard DW; Davis JJ; Shukla M; Nguyen M; Saavedra MO; Yerramilli P; Pruitt L; Subedi S; Kuo HC; Hendrickson H; Eskandari G; Nguyen HAT; Long JH; Kumaraswami M; Goike J; Boutz D; Gollihar J; McLellan JS; Chou CW; Javanmardi K; Finkelstein IJ; Musser JM
    mBio; 2020 Oct; 11(6):. PubMed ID: 33127862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Human neutralizing antibodies elicited by SARS-CoV-2 infection.
    Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L
    Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
    McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
    Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Designing a novel mRNA vaccine against SARS-CoV-2: An immunoinformatics approach.
    Ahammad I; Lira SS
    Int J Biol Macromol; 2020 Nov; 162():820-837. PubMed ID: 32599237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 46. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A human monoclonal antibody blocking SARS-CoV-2 infection.
    Wang C; Li W; Drabek D; Okba NMA; van Haperen R; Osterhaus ADME; van Kuppeveld FJM; Haagmans BL; Grosveld F; Bosch BJ
    Nat Commun; 2020 May; 11(1):2251. PubMed ID: 32366817
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
    Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
    Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Strategies for vaccine development of COVID-19].
    Yang L; Tian D; Liu W
    Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):593-604. PubMed ID: 32347054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures.
    Eroshenko N; Gill T; Keaveney MK; Church GM; Trevejo JM; Rajaniemi H
    Nat Biotechnol; 2020 Jul; 38(7):789-791. PubMed ID: 32504046
    [No Abstract]   [Full Text] [Related]  

  • 51. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.
    Noorimotlagh Z; Karami C; Mirzaee SA; Kaffashian M; Mami S; Azizi M
    Int Immunopharmacol; 2020 Sep; 86():106738. PubMed ID: 32683296
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
    Corbett KS; Flynn B; Foulds KE; Francica JR; Boyoglu-Barnum S; Werner AP; Flach B; O'Connell S; Bock KW; Minai M; Nagata BM; Andersen H; Martinez DR; Noe AT; Douek N; Donaldson MM; Nji NN; Alvarado GS; Edwards DK; Flebbe DR; Lamb E; Doria-Rose NA; Lin BC; Louder MK; O'Dell S; Schmidt SD; Phung E; Chang LA; Yap C; Todd JM; Pessaint L; Van Ry A; Browne S; Greenhouse J; Putman-Taylor T; Strasbaugh A; Campbell TA; Cook A; Dodson A; Steingrebe K; Shi W; Zhang Y; Abiona OM; Wang L; Pegu A; Yang ES; Leung K; Zhou T; Teng IT; Widge A; Gordon I; Novik L; Gillespie RA; Loomis RJ; Moliva JI; Stewart-Jones G; Himansu S; Kong WP; Nason MC; Morabito KM; Ruckwardt TJ; Ledgerwood JE; Gaudinski MR; Kwong PD; Mascola JR; Carfi A; Lewis MG; Baric RS; McDermott A; Moore IN; Sullivan NJ; Roederer M; Seder RA; Graham BS
    N Engl J Med; 2020 Oct; 383(16):1544-1555. PubMed ID: 32722908
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
    Wang F; Kream RM; Stefano GB
    Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies.
    Ahmed SF; Quadeer AA; McKay MR
    Viruses; 2020 Feb; 12(3):. PubMed ID: 32106567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
    Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
    Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
    [TBL] [Abstract][Full Text] [Related]  

  • 57. mRNA Vaccines: Possible Tools to Combat SARS-CoV-2.
    Yi C; Yi Y; Li J
    Virol Sin; 2020 Jun; 35(3):259-262. PubMed ID: 32524253
    [No Abstract]   [Full Text] [Related]  

  • 58. Overview of the current promising approaches for the development of an effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.
    Mirzaei R; Mohammadzadeh R; Mahdavi F; Badrzadeh F; Kazemi S; Ebrahimi M; Soltani F; Kazemi S; Jeda AS; Darvishmotevalli M; Yousefimashouf R; Keyvani H; Karampoor S
    Int Immunopharmacol; 2020 Nov; 88():106928. PubMed ID: 32862110
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of glycoscience in fighting Covid-19.
    Adamo R; Sonnino S
    Glycoconj J; 2020 Aug; 37(4):511-512. PubMed ID: 32504168
    [No Abstract]   [Full Text] [Related]  

  • 60. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.
    Gupta T; Gupta SK
    Int Immunopharmacol; 2020 Sep; 86():106717. PubMed ID: 32585611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.